{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:13:09Z","timestamp":1789053189778,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>FVC percent predicted (FVC%) is the primary outcome measure in clinical trials of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over time, it is important to define whether these changes are clinically meaningful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the reliability and the minimal clinically important differences (MCID) for FVC% in the Scleroderma Lung Study I and II (SLS-I and -II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from SLS-I and -II (N\u2009=\u2009300), we evaluated the test-retest reliability for FVC% (screening vs. baseline) using intraclass correlation. MCID estimates at 12 months were calculated in the pooled cohort (SLS-I and -II) using two anchors: Transition Dyspnea Index (\u2265change of 1.5 units for improvement and worsening, respectively) and the Medical Outcomes Short Form-36 Health Transition question (\u201cCompared with one year ago, how would you rate your health in general now\u201d?), where \u201csomewhat better\u201d or \u201csomewhat worse\u201d were defined as the MCID estimates. We next assessed the association of MCID estimates for improvement and worsening of FVC% with patient-reported outcomes (PROs) and computer-assisted quantitation of extent of fibrosis (QLF) and of total interstitial lung disease (QILD) on high-resolution computed tomography. Student\u2019s t test was used to compare the mean difference in outcomes between the MCID improvement\/worsening and the \u201cno change\u201d group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Reliability of FVC%, assessed at a mean of 34 days, intraclass correlation was 0.93 for the pooled cohort. The MCID estimates for the pooled cohort at 12 months for FVC% improvement ranged from 3.0% to 5.3% and for worsening from \u22123.0% to \u22123.3%. FVC% improvement by greater than or equal to MCID was associated with either statistically significant or numerical improvements in some PROs, QILD, and QLF, whereas FVC% worsening greater than or equal to MCID was associated with statistically significant or numerical worsening of PROs, QILD, and QLF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FVC% has acceptable test-retest reliability, and we have provided the MCID estimates for FVC% in systemic sclerosis interstitial lung disease\u2013based changes at 12 months from baseline in two clinical trials.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT00004563 for SLS-I and NCT00883129 for SLS-II).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201709-1845oc","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T15:08:14Z","timestamp":1509721694000},"page":"644-652","source":"Crossref","is-referenced-by-count":111,"title":["Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)"],"prefix":"10.1093","volume":"197","author":[{"given":"Suzanne","family":"Kafaja","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Wilhalme","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-hong","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, University of California, Los Angeles, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, University of California, Los Angeles, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Volkmann","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2026032023160352300_bib1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026032023160352300_bib2","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026032023160352300_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"Sime\u00f3n-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2026032023160352300_bib4","doi-asserted-by":"crossref","first-page":"v27","DOI":"10.1093\/rheumatology\/kex203","article-title":"Interstitial lung disease points to consider for clinical trials in systemic sclerosis","volume":"56","author":"Khanna","year":"2017","journal-title":"Rheumatology"},{"key":"2026032023160352300_bib5","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2026032023160352300_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026032023160352300_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00019053-200018050-00001","article-title":"The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?","volume":"18","author":"Hays","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"2026032023160352300_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026032023160352300_bib9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/art.22580","article-title":"Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study","volume":"56","author":"Khanna","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026032023160352300_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"2026032023160352300_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St. George\u2019s Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"2026032023160352300_bib12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/rheumatology\/keu456","article-title":"Reliability, validity and responsiveness to change of the Saint George\u2019s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis","volume":"54","author":"Wallace","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026032023160352300_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2026032023160352300_bib14","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO;2-J","article-title":"Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2026032023160352300_bib15","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"key":"2026032023160352300_bib16","first-page":"832","article-title":"Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial","volume":"32","author":"Khanna","year":"2005","journal-title":"J Rheumatol"},{"key":"2026032023160352300_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"2026032023160352300_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"key":"2026032023160352300_bib19","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"Kim","year":"2011","journal-title":"Eur Radiol"},{"key":"2026032023160352300_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2015-208929","article-title":"Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment","volume":"75","author":"Kim","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026032023160352300_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol Bull"},{"key":"2026032023160352300_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"key":"2026032023160352300_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/thx.2009.113498","article-title":"The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference","volume":"65","author":"Swigris","year":"2010","journal-title":"Thorax"},{"key":"2026032023160352300_bib24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler\u2019s Transition Dyspnoea Index in a large randomized controlled trial: results from the Scleroderma Lung Study","volume":"48","author":"Khanna","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2026032023160352300_bib25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023160352300_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"2026032023160352300_bib27","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10620-017-4499-9","article-title":"Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales","volume":"62","author":"Khanna","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2026032023160352300_bib28","volume-title":"Statistical power analysis for the behavioral sciences.","author":"Cohen","year":"1977","edition":"1st ed."},{"key":"2026032023160352300_bib29","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032023160352300_bib30","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032023160352300_bib31","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026032023160352300_bib32","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase ii study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"2026032023160352300_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00422218","article-title":"Psychometric considerations in evaluating health-related quality of life measures","volume":"2","author":"Hays","year":"1993","journal-title":"Qual Life Res"},{"key":"2026032023160352300_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032023160352300_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1378\/chest.80.1.97","article-title":"Changes in measured spirometric indices. What is significant?","volume":"80","author":"Pennock","year":"1981","journal-title":"Chest"},{"key":"2026032023160352300_bib36","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"2026032023160352300_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","article-title":"Clinician-reported outcome assessments of treatment benefit: report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force","volume":"20","author":"Powers","year":"2017","journal-title":"Value Health"},{"key":"2026032023160352300_bib38","first-page":"A1138","article-title":"Transitional voxel-wise changes in the interstitial lung disease on high resolution computed tomography using Scleroderma Lung Study-II [abstract]","volume":"193","author":"Kim","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/5\/644\/67122341\/ajrccm_197_5_644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/5\/644\/67122341\/ajrccm_197_5_644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:16:16Z","timestamp":1774062976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/197\/5\/644\/8498591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201709-1845oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,3,1]]}}}